Top-News

Sucampo Pharmaceuticals Inc News

Keine aktuellen Kursdaten verfügbar
WKN: A0KEZN
ISIN: US8649091068
Typ: Aktie

Sucampo Pharmaceuticals Inc News

13.02.18 - PR Newswire
Mallinckrodt Completes Acquisition Of Sucampo Pharmaceuticals, Inc.
Mallinckrodt Completes Acquisition Of Sucampo Pharmaceuticals, Inc. PR Newswire
06.02.18 - PR Newswire
Boyd Gaming Set to Join S&P MidCap 400; Ring Energy, James River Group Holdings and EVERTEC to Join S&P SmallCap 600
Boyd Gaming Set to Join S&P MidCap 400; Ring Energy, James River Group Holdings and EVERTEC to Join S&P SmallCap 600 PR Newswire
25.01.18 - PR Newswire
Monteverde & Associates PC Files Class Action Lawsuit On Behalf Of Shareholders Of Sucampo Pharmaceuticals, Inc. In The District Of Maryland
Monteverde & Associates PC Files Class Action Lawsuit On Behalf Of Shareholders Of Sucampo Pharmaceuticals, Inc. In The District Of Maryland PR Newswire
21.01.18 - PR Newswire
Lifshitz & Miller LLP Announces Investigation of Advanced Micro Devices, Aflac Incorporated, DST Systems, Inc., Forum Merger Corporation, GoPro, Inc., Sucampo Pharmaceuticals, Inc. and ZAIS Group
Lifshitz & Miller LLP Announces Investigation of Advanced Micro Devices, Aflac Incorporated, DST Systems, Inc., Forum Merger Corporation, GoPro, Inc., Sucampo Pharmaceuticals, ...
02.01.18 - PR Newswire
Wolf Popper LLP Investigates the Proposed Acquisition of Sucampo Pharmaceuticals, Inc. by Mallinckrodt plc
Wolf Popper LLP Investigates the Proposed Acquisition of Sucampo Pharmaceuticals, Inc. by Mallinckrodt plc PR Newswire
01.01.18 - PR Newswire
SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Sucampo Pharmaceuticals, Inc. -- SCMP
SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Sucampo Pharmaceuticals, Inc. -- SCMP PR Newswire
26.12.17 - PR Newswire
Mallinckrodt To Acquire Sucampo Pharmaceuticals For Approximately $1.2 Billion
Mallinckrodt To Acquire Sucampo Pharmaceuticals For Approximately $1.2 Billion -- Immediately accretive transaction includes development and commercial assets including ...
19.04.17 - GlobeNewswire
Veröffentlichung einer neuen Studie zu VTS-270 für die Behandlung von Morbus Niemann-Pick Typ C1 im Online-Fachjournal PLOS ONE Advances Science
Veröffentlichung einer neuen Studie zu VTS-270 für die Behandlung von Morbus Niemann-​Pick Typ C1 im Online-​Fachjournal PLOS ONE Advances Science ROCKVILLE, Maryland, ...
18.04.17 - GlobeNewswire
New Study Published in PLOS ONE Advances Science Around VTS-270 for Treatment of Niemann-Pick Disease Type C1
New Study Published in PLOS ONE Advances Science Around VTS-270 for Treatment of Niemann-​Pick Disease Type C1 ROCKVILLE, Md., April 18, 2017 (GLOBE NEWSWIRE) -- ...
04.04.17 - GlobeNewswire
Sucampo übernimmt Vtesse Inc.
Sucampo übernimmt Vtesse Inc. Transaktion in Höhe von 200 Millionen USD Vorauszahlung Diversifiziert die Pipeline mit Spätphasen-​Programm zur Behandlung der Niemann-...
03.04.17 - DGAP
Sucampo Acquires Vtesse Inc.
DGAP-News: Sucampo Pharmaceuticals, Inc. Sucampo Acquires Vtesse Inc. 03.04.2017 / 12:30 The issuer is solely responsible for the content of this announcement. Transaction ...
03.04.17 - GlobeNewswire
Sucampo Acquires Vtesse Inc.
Sucampo Acquires Vtesse Inc. Transaction Valued at $200 Million Upfront Diversifies Pipeline with Late Stage Program in Niemann-​Pick Disease Type C1 (NPC-1) Increases ...
17.02.17 - PR Newswire
Sucampo Pharmaceuticals Set to Join S&P SmallCap 600
Sucampo Pharmaceuticals Set to Join S&P SmallCap 600 PR Newswire
09.11.15 - PR Newswire
Mast Therapeutics Announces Appointment Of Peter Greenleaf To Board of Directors
Mast Therapeutics Announces Appointment Of Peter Greenleaf To Board of Directors PR Newswire
25.03.14 - PR Newswire
VLP Therapeutics Appoints Dr. Ryuji Ueno as Chair and Chief Medical Officer
VLP Therapeutics Appoints Dr. Ryuji Ueno as Chair and Chief Medical Officer PR Newswire
13.03.14 - DGAP
Sucampo Receives Notice that Second Indication for AMITIZA for Opioid-Induced Constipation Is Not Approved by Medicines and Healthcare Products Regulatory Agency in U.K.
DGAP-News: Sucampo Pharmaceuticals, Inc. / Sucampo Receives Notice that Second Indication for AMITIZA for Opioid-​Induced Constipation Is Not Approved by Medicines and Health...
10.02.14 - DGAP
Sucampo Names Peter Greenleaf Chief Executive Officer
DGAP-News: Sucampo Pharmaceuticals, Inc. / Sucampo Names Peter Greenleaf Chief Executive Officer 10.02.2014 / 22:02 --------------------------------------------------------------------- BETHE...
22.10.13 - DGAP
Sucampo Announces Completion of Patient Enrollment in a Phase 3 Clinical Study of Unoprostone Isopropyl for Retinitis Pigmentosa
Sucampo Pharmaceuticals, Inc. 22.10.2013 02:00 --------------------------------------------------------------------------- Study Conducted by Development Partner R-Tech Ueno and Majority-...
13.09.13 - DGAP
Sucampo to Present Data on AMITIZA(R) (lubiprostone) in Chronic Idiopathic Constipation at Annual Meeting of the Swiss Society of Gastroenterology
Sucampo Pharmaceuticals, Inc. 13.09.2013 01:00 --------------------------------------------------------------------------- BETHESDA, Md., 2013-09-13 01:00 CEST (GLOBE NEWSWIRE) -- Sucamp...

Newssuche

Videos

newspaper
18.04.24 -8,67%
Technical Trading: Gold mit weiterem Potenzial
Gold Long Typ: Turbo Open End WKN: UH4MU6 Hebel: 4,67 Laufzeit: OpenEnd Einstieg: Market ... Mehr »